All News
POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts.
Tofa & bari took biggest hits; upa growth slowed but offset losses.
Real-world prescribing adapts—but doesn’t abandon.
@RheumNow #EULAR2025 https://t.co/QZ5haW2vhX
Jiha Lee JihaRheum ( View Tweet)
?fishing for + results #EULAR2025
⚠️opinion
be aware that results do not live or die on P values
Impt findings beyond primary endpoints may be Impt beyond P<0.05
Conversely
Unexpected P values in a database
❎interpret w caution
Consider as hypothesis only
@RheumNow
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
ACQUIVAS: RTX-treated AAV patients had poor response to #pneumococcal vaccine PCV-13 (8% vs 45% in non-RTX). Boosting w/ PPV-23 helped a few but 48% failed to mount robust response. Time to rethink vaccine strategies in RTX-treated patients?
@RheumNow #EULAR2025 #OP0173 https://t.co/soU5qfwRib
Mrinalini Dey DrMiniDey ( View Tweet)
#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission.
@RheumNow #EULAR2025 #OP0189
Mrinalini Dey DrMiniDey ( View Tweet)
BioDMARDs reduce polyimmunity in RA
Danish Registry based cohort study 5 yrs follow up
25000+ pts
Polyimmunity in csDMARDs treated group 2.2% vs. 1.7% in bioDMARDs group
HR 0.74
Most frequent autoimmune thyroid disease
POS0161 #EULAR2025 @RheumNow https://t.co/9T0mhoUuqs
Aurelie Najm AurelieRheumo ( View Tweet)
Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years.
Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ
Dr. John Cush RheumNow ( View Tweet)
#Oninutuzumab works in
#lupus #nephritis #LN
no matter how you vary the
#renal #responses
Of various definitions of
#Complete & #Partial #renal #responses
abst#OP0006
#EULAR25 @eular_org @RheumNow
Not surprised 😲 https://t.co/Zn2lXkddez
Links:
Janet Pope Janetbirdope ( View Tweet)
1 shot will do!
#symptomatic #Knee #OA given #gene #therapy #intra-#articular
Seemed to last up to 104 weeks!
But no placebo
small safety study but sustained #WOMAC responses
Needs large #RCT but v interesting
#EULAR2025 @RheumNow @eular_org
Abst# POS0492 https://t.co/hqTqBorrbA
Links:
Janet Pope Janetbirdope ( View Tweet)
Exciting results from ARGO trial:
-Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA.
-Met primary endpoint of ACR50 at week 12 vs PBO.
-62% achieved MDA
-48% achieved composite of ACR 70+PASI 100
Looking forward to phase 3 results!!!
Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS
Links:
Adela Castro AdelaCastro222 ( View Tweet)
So much needed in SLE and pregnancy
1. Risk stratification at diagnosis
2. Pregnancy counseling at dx and >1 y before pregnancy
3. Close collab with GYN necessary
4. Challenging management given gaps in evidence.
#EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452
Links:
Adela Castro AdelaCastro222 ( View Tweet)
SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks:
•Early TNFi: 3.7
•Combo csDMARDs: 4.1
•Step-up csDMARDs: 4.7
Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Cool technology reduces dose interval of #IL17AFi
To…every 6 to 12 months!
#Antibody ORKA-002 has end of arms w YTE substitution prolonging circulation of drug
Lasts longer than #bimekizumab
Easier for adherence!
#EULAR2025 @RheumNow @eular_org #abstPOS0016 https://t.co/KcKaIe0WMs
Links:
Janet Pope Janetbirdope ( View Tweet)
🚨 Type I IFN in Pediatric SLE: Expanded Insights!
•🩺 IFN-I Impact: Fuels pediatric SLE; drives T-cell autoreactivity, autoantibody production, proinflammatory cytokines.
•📈 Key Pathways: Plasmacytoid dendritic cells overproduce IFN-I via cGAS-STING-TBK1, TLR4/TLR9; https://t.co/4i3MktOoVd
Links:
Dr.Mukesh , MD , DM dr_immuno29 ( View Tweet)
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Phase 3 of POETYK-PsA-2:
-Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains.
-Clinical efficacy maintained until week 52.
-No major safety signals reported.
-Notably high placebo response rates.
Abstract
Adela Castro AdelaCastro222 ( View Tweet)
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis?
🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro
#EULAR2025
OP0090
@RheumNow
#Strategy https://t.co/W8fuzSgxbJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
